Shamis & Gentile, P.A. is investigating claims on behalf of investors of agilon health, inc. (“agilon health” or the “Company”) (AGL). Impacted investors are advised to contact the firm now.
The investigation concerns whether agilon health and certain of its officers and/or directors engaged in securities fraud or other unlawful business practices. The investigation is presently focused on potential violations of the federal securities laws during the period of between February 25, 2025 and August 4, 2025.
On August 4, 2025, after the market closed, agilon health, inc. reported negative second quarter 2025 results, including a decline in revenue to $1.40 billion from $1.48 billion year-over-year and a medical margin that swung to negative $53 million from a positive $106 million the prior year. The Company also withdrew its 2025 guidance and disclosed that it would record an $85 million cumulative write-down related to overstated 2024-2025 risk-adjustment revenues.
On this news, agilon health, inc.’s stock price fell approximately 24.7%, dropping from around $2.20 to $1.60 per share, on August 5, 2025.
Shamis & Gentile, P.A. stands out as an advocate for investors who are victims of securities fraud. The firm is committed to securing recoveries for investors who have incurred damages due to false and misleading statements or other corporate misconduct by public companies. Shamis Gentile has recovered over $1 billion for consumers nationwide. Its extensive experience, expertise, and resources enable the firm to resolve disputes in a wide range of matters, including class actions, mass torts and mass arbitrations.
Attorney advertising. Prior results do not guarantee similar outcomes.
